Clinical trial · no report yet · Phase 1
MonumenTAL-2
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- NCT05050097 ↗
- Active not recruiting
- Janssen Research & Development, LLC
- 19 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 9 | |
| Podcasts | 5 | |
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Phase
- Phase 1
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Talquetamab; Carfilzomib; Daratumumab SC; Lenalidomide; Pomalidomide
- Arms
- Treatment Regimen A: Talquetamab + Carfilzomib · Experimental
- Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib · Experimental
- Treatment Regimen C: Talquetamab + Lenalidomide · Experimental
- Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide · Experimental
- Treatment Regimen E: Talquetamab + Pomalidomide · Experimental
- Enrollment
- 166
- Primary outcomes
- Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
- Number of Participants with AEs by Severity
- Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters
- Number of Participants with Dose Limiting Toxicity (DLT)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Sep 22, 2021
- Primary completion
- Mar 31, 2025
- Results posted
- No
- Registry record
- NCT05050097 · updated Sep 28, 2026